English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Treatment for patients with newly diagnosed medulloblastoma includes surgical resection followed by craniospinal radiotherapy. Adjuvant chemotherapy has been shown to increase the cure rate with high risk or average risk disease and is now a standard part of contemporary management (Gajjor et al., 99). Advance in surgery and radiotherapy techniques have improved results in the last few decades (Paker 1999). These procedures have important early and long term morbidity that must be weighted in order to offer the patient an acceptable risk-beniefit likelihood. The purpose of this study was to analyze the various clinical and prognostic features which might affect the survival of medulloblastoma and to asses the response of patients to treatment. This study includes 288 patients with medulloblastoma who were treated in both Neurosurgical and Radiation Oncology Departments during the period 1981 and 2000. Statistical analysis has proven that the median survival was not affected significantly by the sex or site of tumor but the most significant variables that affected the median survival were the extent of surgery and stage of the tumor, age and histopathology. Shunt operation reduces the incidence of post operative mortality markedly.

Experience of 20 years in Management of Medullohlastoma ( A long term Retro spective study)